PUBLISHER: DelveInsight | PRODUCT CODE: 2082694
PUBLISHER: DelveInsight | PRODUCT CODE: 2082694
Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2036
Focal Segmental Glomerulosclerosis (FSGS) Insights and Trends
- FSGS is a rare kidney disorder characterized by scarring (sclerosis) of parts of the glomeruli, leading to significant protein loss in urine.
- Lack of validated non-invasive biomarkers limits early detection and patient stratification. Hence, the diagnosis relies heavily on a kidney biopsy.
- A major unmet need in FSGS is poor disease understanding and heterogeneity, as patients have varied underlying causes (genetic, primary, secondary), making it difficult to predict disease course and stratify patients for appropriate management.
DelveInsight's 'Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis (FSGS), historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.
Focal Segmental Glomerulosclerosis (FSGS) Understanding and Diagnosis Algorithm
Focal Segmental Glomerulosclerosis (FSGS) Overview
FSGS is a rare but serious kidney disorder characterized by scarring (sclerosis) in parts (segments) of some (focal) glomeruli-the filtering units of the kidney. It can be classified as primary (idiopathic) or secondary, with secondary forms linked to conditions such as obesity, viral infections, or genetic mutations. FSGS often presents with proteinuria (excess protein in urine), which can progress to nephrotic syndrome and eventually chronic kidney disease or end-stage renal disease if untreated. The disease burden is increasing globally due to rising rates of risk factors like diabetes and hypertension, making it a growing concern in nephrology.
Focal Segmental Glomerulosclerosis (FSGS) Diagnosis
Diagnosis of FSGS typically involves a combination of clinical evaluation, laboratory testing, and confirmatory procedures. Initial signs include persistent proteinuria, edema, and reduced kidney function, detected through urine analysis and blood tests measuring creatinine and albumin levels. However, a definitive diagnosis requires a kidney biopsy, where histological examination reveals segmental scarring of glomeruli. Advances in diagnostic approaches, including genetic testing and biomarker identification, are improving the ability to differentiate between primary and secondary forms of the disease, which is critical for selecting the most appropriate treatment strategy.
Focal Segmental Glomerulosclerosis (FSGS) Epidemiology
Key Findings from Focal Segmental Glomerulosclerosis (FSGS) Epidemiological Analysis and Forecast
- According to analysis, in 2025, the total diagnosed prevalent cases of FSGS in the 7MM were approximately 213,000 and are expected to increase through 2036.
- The United States accounted for the highest diagnosed prevalent cases of FSGS, representing approximately 36% of total cases in the 7MM in 2025.
- Among the EU4 and the UK, the UK accounted for the highest diagnosed prevalent cases of FSGS in 2025, followed by Germany.
- The prevalence of FSGS was the highest in individuals aged 18-64.
- In 2025, primary FSGS was found to be the more prevalent type among the two forms of FSGS, accounting for approximately 80% of the diagnosed population in the United States.
- DelveInsight estimates that Japan has more diagnosed prevalent cases of FSGS in males (61%) than females (39%).
Scope of the Report:
- The report covers a segment of a descriptive overview of FSGS, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Focal Segmental Glomerulosclerosis (FSGS) Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of FSGS? What will be the growth opportunities across the 7MM concerning the patient population with FSGS?
- What is the historical and forecasted FSGS patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
- Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology Methodology of Focal Segmental Glomerulosclerosis (FSGS)
5. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Overview at a Glance
- 5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background And Overview of Focal Segmental Glomerulosclerosis (FSGS)
- 6.1. Introduction
- 6.2. Causes
- 6.3. Signs And Symptoms
- 6.4. Diagnosis
- 6.4.1. Differential Diagnosis
- 6.4.2. Diagnostic Algorithm
- 6.4.3. Diagnostic Guidelines
7. Epidemiology and Patient Population of Focal Segmental Glomerulosclerosis (FSGS)
- 7.1. Key Findings
- 7.2. Assumption and Rationale
- 7.3. Total Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the 7MM
- 7.4. The United States
- 7.4.1. Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the United States
- 7.4.2. Gender-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the United States
- 7.4.3. Age-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the United States
- 7.4.4. Type-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in the United States
- 7.5. EU4 and the UK
- 7.5.1. Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
- 7.5.2. Gender-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
- 7.5.3. Age-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
- 7.5.4. Type-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in EU4 and the UK
- 7.6. Japan
- 7.6.1. Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in Japan
- 7.6.2. Gender-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in Japan
- 7.6.3. Age-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in Japan
- 7.6.4. Type-specific Diagnosed Prevalent Cases of Focal Segmental Glomerulosclerosis (FSGS) in Japan
8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables
- Table 1: Summary of FSGS Epidemiology (2022-2036)
- Table 2: Key Events
- Table 3: Lipid Screening for Patients Not Already on Statins
- Table 4: Classification of Evidence Levels of Epidemiological Studies
- Table 5: Comprehensive Risk Assessment
- Table 6: Classes of Recommendation
- Table 7: Total Diagnosed Prevalent Cases of FSGS in the 7MM, in '000' (2022-2036)
- Table 8: Total Diagnosed Prevalent Cases of FSGS in the US, in '000' (2022-2036)
- Table 9: Gender-specific Diagnosed Prevalent Cases of FSGS in the US, in '000' (2022-2036)
- Table 10: Age-specific Diagnosed Prevalent Cases of FSGS in the US, in '000' (2022-2036)
- Table 11: Comorbidity-specific Diagnosed Prevalent Cases of FSGS in the US, in '000' (2022-2036)
- Table 12: Total Diagnosed Prevalent Cases of FSGS in EU4 and the UK, in '000' (2022-2036)
- Table 13: Gender-specific Diagnosed Prevalent Cases of FSGS in EU4 and the UK, in '000' (2022-2036)
- Table 14: Age-specific Diagnosed Prevalent Cases of FSGS in EU4 and the UK, in '000' (2022-2036)
- Table 15: Comorbidity-specific Diagnosed Prevalent Cases of FSGS in EU4 and the UK, in '000' (2022-2036)
- Table 16: Total Diagnosed Prevalent Cases of FSGS in Japan, in '000' (2022-2036)
- Table 17: Gender-specific Diagnosed Prevalent Cases of FSGS in Japan, in '000' (2022-2036)
- Table 18: Age-specific Diagnosed Prevalent Cases of FSGS in Japan, in '000' (2022-2036)
- Table 19: Comorbidity-specific Diagnosed Prevalent Cases of FSGS in Japan, in '000' (2022-2036)
List of Figures
- Figure 1: Summary of FSGS Epidemiology (2022-2036)
- Figure 2: Key Events
- Figure 3: Lipid Screening for Patients Not Already on Statins
- Figure 4: Classification of Evidence Levels of Epidemiological Studies
- Figure 5: Comprehensive Risk Assessment
- Figure 6: Classes of Recommendation
- Figure 7: Total Diagnosed Prevalent Cases of FSGS in the 7MM, in '000' (2022-2036)
- Figure 8: Total Diagnosed Prevalent Cases of FSGS in the US, in '000' (2022-2036)
- Figure 9: Gender-specific Diagnosed Prevalent Cases of FSGS in the US, in '000' (2022-2036)
- Figure 10: Age-specific Diagnosed Prevalent Cases of FSGS in the US, in '000' (2022-2036)
- Figure 11: Comorbidity-specific Diagnosed Prevalent Cases of FSGS in the US, in '000' (2022-2036)
- Figure 12: Total Diagnosed Prevalent Cases of FSGS in EU4 and the UK, in '000' (2022-2036)
- Figure 13: Gender-specific Diagnosed Prevalent Cases of FSGS in EU4 and the UK, in '000' (2022-2036)
- Figure 14: Age-specific Diagnosed Prevalent Cases of FSGS in EU4 and the UK, in '000' (2022-2036)
- Figure 15: Comorbidity-specific Diagnosed Prevalent Cases of FSGS in EU4 and the UK, in '000' (2022-2036)
- Figure 16: Total Diagnosed Prevalent Cases of FSGS in Japan, in '000' (2022-2036)
- Figure 17: Gender-specific Diagnosed Prevalent Cases of FSGS in Japan, in '000' (2022-2036)
- Figure 18: Age-specific Diagnosed Prevalent Cases of FSGS in Japan, in '000' (2022-2036)
- Figure 19: Comorbidity-specific Diagnosed Prevalent Cases of FSGS in Japan, in '000' (2022-2036)
- Figure 20: Patient Journey of FSGS
